File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Role of nicotinic acid in raising high-density lipoprotein cholesterol (HDL-C) to reduce cardiovascular risk: An Asian/Pacific consensus

TitleRole of nicotinic acid in raising high-density lipoprotein cholesterol (HDL-C) to reduce cardiovascular risk: An Asian/Pacific consensus
Authors
KeywordsAsia
Coronary heart disease
High-density lipoprotein cholesterol
Metabolic syndrome
Type 2 diabetes
Issue Date2005
PublisherSage Publications Ltd.. The Journal's web site is located at http://dvd.sagepub.com/
Citation
British Journal Of Diabetes And Vascular Disease, 2005, v. 5 SUPPL. 2, p. S1-S16 How to Cite?
AbstractCardiovascular disease is a leading cause of morbidity and mortality in Asia, and the burden of disease is expected to rise further in the 21st century. As in Western populations, dyslipidaemia is an important cardiovascular risk factor in Asian people. International guidelines focus on reduction of low-density lipoprotein cholesterol (LDL-C) for prevention and treatment of coronary heart disease (CHD). However, increasing body mass index and prevalence of type 2 diabetes and metabolic syndrome in Asia have highlighted the importance of low levels of high-density lipoprotein cholesterol (HDL-C) as a coronary risk factor. Therapeutic lifestyle changes and pharmacological intervention aimed at raising HDL-C, should benefit such patients. Weight loss and physical exercise are important interventions for raising HDL-C. However, to achieve target HDL-C levels pharmacological intervention is usually necessary. Current treatment options include statins, fibrates and nicotinic acid, either as monotherapy or in combination. Statins are generally regarded as the foundation of lipid-modifying therapy. Mainly via reduction of LDL-C. Both fibrates and nicotinic acid are effective in raising HDL-C levels, and reducing triglyceride-rich lipoproteins. The efficacy and safety profile of nicotinic acid demonstrated in Western populations indicates the clinical benefits of this therapy either alone or in combination with a statin. Based on the available evidence, the Pan-Asian Consensus Panel recommends that HDL-C levels should be raised to at least 1.0 mmol/L (40 mg/dL) in Asian patients with CHD or with a high level of risk for premature vascular disease, including patients at high risk with type 2 diabetes or the metabolic syndrome.
Persistent Identifierhttp://hdl.handle.net/10722/91464
ISSN
2015 SCImago Journal Rankings: 0.231
References

 

DC FieldValueLanguage
dc.contributor.authorBarter, PJen_HK
dc.contributor.authorO'Brien, Ren_HK
dc.contributor.authorWatts, GFen_HK
dc.contributor.authorZhu, Jen_HK
dc.contributor.authorHu, Den_HK
dc.contributor.authorHo, CCen_HK
dc.contributor.authorTomlinson, Ben_HK
dc.contributor.authorCheung, BMYen_HK
dc.contributor.authorAdam, JMFen_HK
dc.contributor.authorTjokroprawiro, Aen_HK
dc.contributor.authorWaspadji, Sen_HK
dc.contributor.authorCho, HKen_HK
dc.contributor.authorHan, KHen_HK
dc.contributor.authorKim, SRen_HK
dc.contributor.authorLin, KKen_HK
dc.contributor.authorChan, SPen_HK
dc.contributor.authorBasit, Aen_HK
dc.contributor.authorPizzaroBorromeo, ABen_HK
dc.contributor.authorPazPacheco, Een_HK
dc.contributor.authorSy, RGen_HK
dc.contributor.authorLee, KOen_HK
dc.contributor.authorLow, LPen_HK
dc.contributor.authorKhue, NTen_HK
dc.contributor.authorBinh, TVen_HK
dc.date.accessioned2010-09-17T10:19:50Z-
dc.date.available2010-09-17T10:19:50Z-
dc.date.issued2005en_HK
dc.identifier.citationBritish Journal Of Diabetes And Vascular Disease, 2005, v. 5 SUPPL. 2, p. S1-S16en_HK
dc.identifier.issn1474-6514en_HK
dc.identifier.urihttp://hdl.handle.net/10722/91464-
dc.description.abstractCardiovascular disease is a leading cause of morbidity and mortality in Asia, and the burden of disease is expected to rise further in the 21st century. As in Western populations, dyslipidaemia is an important cardiovascular risk factor in Asian people. International guidelines focus on reduction of low-density lipoprotein cholesterol (LDL-C) for prevention and treatment of coronary heart disease (CHD). However, increasing body mass index and prevalence of type 2 diabetes and metabolic syndrome in Asia have highlighted the importance of low levels of high-density lipoprotein cholesterol (HDL-C) as a coronary risk factor. Therapeutic lifestyle changes and pharmacological intervention aimed at raising HDL-C, should benefit such patients. Weight loss and physical exercise are important interventions for raising HDL-C. However, to achieve target HDL-C levels pharmacological intervention is usually necessary. Current treatment options include statins, fibrates and nicotinic acid, either as monotherapy or in combination. Statins are generally regarded as the foundation of lipid-modifying therapy. Mainly via reduction of LDL-C. Both fibrates and nicotinic acid are effective in raising HDL-C levels, and reducing triglyceride-rich lipoproteins. The efficacy and safety profile of nicotinic acid demonstrated in Western populations indicates the clinical benefits of this therapy either alone or in combination with a statin. Based on the available evidence, the Pan-Asian Consensus Panel recommends that HDL-C levels should be raised to at least 1.0 mmol/L (40 mg/dL) in Asian patients with CHD or with a high level of risk for premature vascular disease, including patients at high risk with type 2 diabetes or the metabolic syndrome.en_HK
dc.languageengen_HK
dc.publisherSage Publications Ltd.. The Journal's web site is located at http://dvd.sagepub.com/en_HK
dc.relation.ispartofBritish Journal of Diabetes and Vascular Diseaseen_HK
dc.subjectAsiaen_HK
dc.subjectCoronary heart diseaseen_HK
dc.subjectHigh-density lipoprotein cholesterolen_HK
dc.subjectMetabolic syndromeen_HK
dc.subjectType 2 diabetesen_HK
dc.titleRole of nicotinic acid in raising high-density lipoprotein cholesterol (HDL-C) to reduce cardiovascular risk: An Asian/Pacific consensusen_HK
dc.typeArticleen_HK
dc.identifier.emailCheung, BMY:mycheung@hku.hken_HK
dc.identifier.authorityCheung, BMY=rp01321en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.scopuseid_2-s2.0-28444436325en_HK
dc.identifier.hkuros180177-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-28444436325&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume5en_HK
dc.identifier.issueSUPPL. 2en_HK
dc.identifier.spageS1en_HK
dc.identifier.epageS16en_HK
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridBarter, PJ=7005927655en_HK
dc.identifier.scopusauthoridO'Brien, R=7403182978en_HK
dc.identifier.scopusauthoridWatts, GF=7202153447en_HK
dc.identifier.scopusauthoridZhu, J=7405693800en_HK
dc.identifier.scopusauthoridHu, D=7402585148en_HK
dc.identifier.scopusauthoridHo, CC=9732808300en_HK
dc.identifier.scopusauthoridTomlinson, B=16423466900en_HK
dc.identifier.scopusauthoridCheung, BMY=7103294806en_HK
dc.identifier.scopusauthoridAdam, JMF=9738259500en_HK
dc.identifier.scopusauthoridTjokroprawiro, A=6602804709en_HK
dc.identifier.scopusauthoridWaspadji, S=8678136400en_HK
dc.identifier.scopusauthoridCho, HK=7403937590en_HK
dc.identifier.scopusauthoridHan, KH=19434590900en_HK
dc.identifier.scopusauthoridKim, SR=35187268000en_HK
dc.identifier.scopusauthoridLin, KK=9738719800en_HK
dc.identifier.scopusauthoridChan, SP=7404255462en_HK
dc.identifier.scopusauthoridBasit, A=9941730200en_HK
dc.identifier.scopusauthoridPizzaroBorromeo, AB=9734860600en_HK
dc.identifier.scopusauthoridPazPacheco, E=24067446000en_HK
dc.identifier.scopusauthoridSy, RG=6603388395en_HK
dc.identifier.scopusauthoridLee, KO=9747100300en_HK
dc.identifier.scopusauthoridLow, LP=36981508300en_HK
dc.identifier.scopusauthoridKhue, NT=9738302500en_HK
dc.identifier.scopusauthoridBinh, TV=12796144600en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats